Chronic subdural haematoma

Czech version

Authors: P. Stejskal; M. Vaverka; L. Hrabálek; M. Hampl
Authors‘ workplace: Neurochirurgická klinika LF UP a FN Olomouc
Published in: Cesk Slov Neurol N 2019; 82(1): 25-29
Category: Review Article
doi: https://doi.org/10.14735/amcsnn201925

Overview

Chronic subdural haematoma represents one of the most frequent diseases which we deal with in common neurosurgical practice. Diagnosis of chronic subdural haematoma is usually determined by a neurologist, but patients with this diagnosis are commonly seen even by other specialists. The aim of this article is to provide a complete overview of etiology, pathophysiology, clinical presentation, diagnostics and treatment of this disease with regard to up to date knowledge and authors‘ experience.

Key words:

chronic subdural haematoma – subdural effusion – hyperfibrinolysis – brain CT – burr-hole craniostomy

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Sources

1. Krupa M. Chronic subdural hematoma: a review of the literature. Part 1. Ann Acad Med Stetin 2009; 55(2): 47– 52.
2. Karibe H, Kameyama M, Kawase M et al. Epidemiology of chronic subdural hematomas. No Shinkei Geka 2011; 39(12): 1149– 1153.
3. Santarius T, Kirkpatrick PJ, Kolias AG et al. Working toward rational and evidence-based treatment of chronic subdural hematoma. Clin Neurosurg 2010; 57: 112– 122.
4. Ducruet AF, Grobelny BT, Zacharia BE et al. The surgical management of chronic subdural hematoma. Neurosurg Rev 2012; 35(2): 155– 169. doi: 10.1007/ s10143-011-0349-y.
5. Drapkin AJ. Chronic subdural hematoma: pathophysiological basis for treatment. Br J Neurosurg 1991; 5(5): 467– 473.
6. Sajanti J, Majamaa K. High concentrations of procollagen propeptides in chronic subdural haematoma and effusion. J Neurol Neurosurg Psychiatry 2003; 74(4): 522– 524.
7. Baechli H, Nordmann A, Bucher HC et al. Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study. Neurosurg Rev 2004; 27(4): 263– 266.
8. Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulation or antithrombotic therapy. J Clin Neurosci 2006; 13(8): 823– 827. doi: 10.1016/ j.jocn.2004.12.013.
9. Lindvall P, Koskinen LO. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci 2009; 16(10): 1287– 1290. doi: 10.1016/ j.jocn.2009.01.001.
10. Markwalder TM. Chronic subdural hematomas: a review. J Neurosurg 1981; 54(5): 637– 645. doi: 10.3171/ jns. 1981.54.5.0637.
11. Chen JC, Levy ML. Causes, epidemiology, and risk factors of chronic subdural hematoma. Neurosurg Clin N Am 2000; 11(3): 399– 406.
12. Sambavian M. An overview of chronic subdural hematoma: experience with 2300 surgical cases. Surg Neurol 1997; 47(5): 418– 422.
13. Murakami H, Hirose Y, Sagoh M et al. Why do chronic subdural hematomas continue to grow slowly and not coagulate? Role of trombomodulin in the mechanism. J Neurosurg 2002; 96(5): 877– 884. doi: 10.3171/ jns. 2002.96.5.0877.
14. Kawamaki Y, Chikama M, Tamiya T et al. Coagulation and fibrinolysis in chronic subdural hematoma. Neurosurgery 1989; 25(1): 25– 29.
15. Suzuki K, Takano S, Nose T et al. Increased concentration of vascular endothelial growth factor (VEGF) in chronic subdural hematoma. J Trauma 1999; 46(3): 532– 533.
16. Weigel R, Schilling L, Schmiedek P. Specific pattern of growth factor distribution in chronic subdural hematoma (CSH): evidence for an angiogenic disease. Acta Neurochir (Wien) 2001; 143(8): 811– 818.
17. Weir B. Oncotic pressure of subdural fluids. J Neurosurg 1980; 53(4): 512– 515. doi: 10.3171/ jns.1980.53.4.0512.
18. Ischikawa T, Kawamura S, Hadeishi H et al. Cerebral blood flow and oxygen metabolism in hemiparetic patiens with chronic subdural hematoma. Quantitative evaluation using positron emission tomography. Surg Neurol 1995; 43(2): 130– 137.
19. Markwalder TM, Steinsiepe KF, Rohner M et al. The course of chronic subdural hematomas after burr-hole craniostomy and closed-system drainage. J Neurosurg 1981; 55(3): 390– 396.
20. Greenberg MS. Chronic subdural hematoma. Handbook of Neurosurgery. 7th ed. New York: Thieme 2010: 899– 902.
21. Nakaguchi H, Tanishima T, Yoshimasu N. Factors in the natural history of chronic subdural hematomas that influence their postoperative recurrence. J Neurosurg 2001; 95(2): 256– 262. doi: 10.3171/ jns.2001.95.2.0256.
22. Chon KH, Lee JM, Koh EJ et al. Independent predictors for recurrence of chronic subdural hematoma. Acta Neurochir 2012; 154(9): 1541– 1548. doi: 10.1007/ s00701-012-1399-9.
23. Senturk S, Guzel A, Bilici A et al. CT and MR imaging of chronic subdural hematomas: a comparative study. Swiss Med Wkly 2010; 140(23– 24): 335– 340. doi: smw-12867.
24. Vaverka M, Kala M. Zkušenosti s léčbou chronického subdurálního hematomu dospělých. Cesk Slov Neurol N 1993; 56/ 89(4): 155– 159.
25. Santarius T, Kirkpatrick PJ, Ganesan D et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. Lancet 2009; 374(9695): 1067– 1073. doi: 10.1016/ S0140-6736(09)61115-6.
26. Sindou M, Ibrahim I, Maarrawi J. Chronic subdural hematomas: twist drill craniostomy with a closed system of drainage, for 48 hours only, is a valuable surgical treatment. Acta Neurochir 2010; 152(3): 545– 546. doi: 10.1007/ s00701-009-0489-9.
27. Belkhair S, Pickett G. One versus double burr holes for treating chronic subdural hematoma meta-analysis. Can J Neurol Sci 2013; 40(1): 56– 60.
28. Yuan Y, Wang QP, Cao YL et al. Burr hole drainage and burr hole drainage with irrigation to treat chronic subdural hematoma: a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97(33): e11827. doi: 10.1097/ MD.0000000000011827.
29. Rodziewicz GS, Chuang WC. Endoscopic removal of organized chronic subdural hematoma. Surg Neurol 1995; 43(6): 569– 572.
30. Takeda N, Sasaki K, Oikawa A et al. A new simple therapeutic method for chronic subdural hematoma without irrigation and drainage. Acta Neurochir (Wien) 2006; 148(5): 541– 546. doi: 10.1007/ s00701-005-0689-x.
31. Kubo S, Takimoto H, Nakata H et al. Carbon dioxide insufflation for chronic subdural haematoma: a simple addition to burr-hole irrigation and closed-system drainage. Br J Neurosurg 2003; 17(6): 547– 550.
32. Neils DM, Singanallur PS, Wang H et al. Recurrence-free chronic subdural hematomas: a retrospective analysis of the instillation of tissue plasminogen activator in addition to twist drill or burr hole drainage in the treatment of chronic subdural hematomas. World Neurosurg 2012; 78(1– 2): 145– 149. doi: 10.1016/ j.wneu.2011.08.032.
33. Gelabert GM, Iglesias PM, Garcia AA et al. Chronicsubdural haematoma: surgical treatment and outcome in 1000 cases. Clin Neurol Neurosurg 2005; 107(3): 223– 229. doi: 10.1016/ j.clineuro.2004.09.015.
34. Santarius T, Qureshi HU, Sivakumaran R et al. The role of external drains and peritoneal conduits in the treatment of recurrent chronic subdural hematoma. World Neurosurg 2010; 73(6): 747– 750. doi: 10.1016/ j.wneu.2010.03.031.
35. Sikahall ME, Salazar PN, Sandoval BB. Chronic subduralhematoma. Surgical management in 100 patients. Cir Cir 2008; 76(3): 199– 203.
36. Chon KH, Lee JM, Koh EJ et al. Independent predictors for recurrence of chronic subdural hematoma. Acta Neurochir (Wien) 2012; 154(9): 1541– 1548. doi: 10.1007/ s00701-012-1399-9.
37. Berghauser Pont LM, Dirven CM, Dippel DW et al. The role of corticosteroids in the management of chronic subdural hematoma: a systematic review. Eur J Neurol 2012; 19(11): 1397– 1403. doi: 10.1111/ j.1468-1331.2012.03768.x.
38. Tanweer O, Frisoli FA, Bravate C ett. al. Tranexamic acid for treatment of residual subdural hematoma after bedside twist-drill evacuation. World Neurosurg 2016; 91: 29– 33. doi: 10.1016/ j.wneu.2016.03.062.
39. Kageyama H, Toyooka T, Tsuzuki N et al. Nonsurgical treatment of chronic subdural hematoma with tranexamic acid. Neurosurg 2013; 119(2): 332– 337. doi: 10.3171/ 2013.3.JNS122162.
40. Iorio MC, Blanchard J, Richer M et al. Tranexamic acid in chronic subdural hematomas (TRACS): study protocol for a randomized controlled trial. Trials 2016; 17(1): 235. doi: 10.1186/ s13063-016-1358-5.
41. Weigel R, Hohenstein A, Schlickum L et al. Angiotensin converting enzyme inhibition for arterial hypertension reduces the risk of recurrence in patiens with chronic subdural hematoma possibly by an antiangiogenic mechanism. Neurosurgery 2007; 61(4): 788– 792. doi: 10.1227/ 01.NEU.0000298907.56012.E8.
42. Tuka V, Janotam T. Warfarin – starý známý a přece stále neznámý. Interní Med 2011; 13(6): 244– 246.
43. Hanley JP. Warfarin reversal. J Clin Pathol 2004; 57(11): 1132– 1139. doi: 10.1136/ jcp.2003.008904.
44. Lankiewicz MW, Hays J, Friedman KD et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4(5): 967– 970. doi: 10.1111/ j.1538-7836.2006.01815.x.
45. Kawamata T, Takeshita M, Kubo O et al. Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol 1995; 44(5): 438– 442.
46. Yeon JY, Kong DS, Hong SC. Safety of early warfarin resumption following burr hole drainage for warfarin-associated subacute or chronic subdural hemorrhage. J Neurotrauma 2012; 29(7): 1334– 1341. doi: 10.1089/ neu.2011.2074.
47. Forster MT, Mathe AK, Senft C et al. The influence of preoperative anticoaglation on outcome and quality of life after surgical treatment of chronic subdural hematoma. J Clin Neurosci 2010; 17(8): 975– 979. doi: 10.1016/ j.jocn.2009.11.023.
48. Mascarenhas L. Illustration of the impact of antiplatelet drugs on the genesis and management of chronic subdural hematoma. Neurochirurgie 2012; 58(1): 47– 51. doi: 10.1016/ j.neuchi.2011.09.005.
49. Ohba S, Kinoshita Y, Nakagawa T et al. The risk factors for recurrence of chronic subdural hematoma. Neurosurg Rev 2013; 36(1): 145– 149. doi: 10.1007/ s10143-012-0396-z.
50. Blažek M, Havel E, Bělobrádková E. Předoperační vyšetření a příprava chirurgického pacienta. Interní Med 2012; 14(11): 422– 428.